Diabetes Metab. 2020 Jan 30
Reduction in HbA1c with SGLT2 inhibitors vs DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: a systematic review of randomized controlled trials.
Scheen AJ
This study compared the reduction of glycated haemoglobin (HbA1c) with sodium-glucose cotransporter type-2 inhibitors (SGLT2is) vs dipeptidyl peptidas ...
Read More
Source: PubMed
Diabetes Res. Clin. Pract. 2020 Jan 29
Effectiveness, safety, and tolerability of vildagliptin or vildagliptin/metformin combination in patients with type 2 diabetes uncontrolled on insulin therapy in a real-world setting in Egypt: the OMEGA study.
El Ebrashy I, El Kafrawy N, Raouf R, Yousry D
To evaluate the effectiveness and safety of vildagliptin or vildagliptin/metformin combination among patients with type 2 diabetes mellitus (T2DM) unc ...
Read More
Source: PubMed
Diabetes Res. Clin. Pract. 2020 Jan 29
The beneficial effects (on cardio-renal system) of glucose-lowering agents with caloric-restriction mimetic properties are subtractive rather than additive.
Prattichizzo F
Read More
Source: PubMed
Gut Microbes 2020 Jan 31
Considering gut microbiota in treatment of type 2 diabetes mellitus.
Adeshirlarijaney A, Gewirtz AT
Advances in the understanding of the pathogenesis of type 2 diabetes mellitus (T2D) have revealed a role for gut microbiota dysbiosis in driving this ...
Read More
Source: PubMed
Eur. J. Pharmacol.
Infliximab ameliorates tumor necrosis factor-alpha exacerbated renal insulin resistance induced in rats by regulating insulin signaling pathway.
Mohamad HE, Asker ME, Keshawy MM, Abdel Aal SM, Mahmoud YK
Infliximab (IFX), a monoclonal antibody for tumor necrosis factor-alpha (TNF-a), is known to restore blood glucose homeostasis. However, its effects o ...
Read More
Source: PubMed
